CASI vs. DARE, ENLV, JAN, THTX, DRRX, FBIO, VIRX, SPRB, IPA, and NXTC
Should you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Daré Bioscience (DARE), Enlivex Therapeutics (ENLV), JanOne (JAN), Theratechnologies (THTX), DURECT (DRRX), Fortress Biotech (FBIO), Viracta Therapeutics (VIRX), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership.
Daré Bioscience currently has a consensus price target of $6.00, suggesting a potential upside of 1,828.02%. CASI Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 329.34%. Given CASI Pharmaceuticals' higher probable upside, analysts clearly believe Daré Bioscience is more favorable than CASI Pharmaceuticals.
6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 5.3% of Daré Bioscience shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Daré Bioscience has a net margin of 0.00% compared to Daré Bioscience's net margin of -79.30%. Daré Bioscience's return on equity of -77.55% beat CASI Pharmaceuticals' return on equity.
Daré Bioscience received 153 more outperform votes than CASI Pharmaceuticals when rated by MarketBeat users. Likewise, 73.18% of users gave Daré Bioscience an outperform vote while only 51.69% of users gave CASI Pharmaceuticals an outperform vote.
Daré Bioscience has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
CASI Pharmaceuticals has higher revenue and earnings than Daré Bioscience. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, Daré Bioscience had 9 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 9 mentions for Daré Bioscience and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.10 beat Daré Bioscience's score of 0.00 indicating that Daré Bioscience is being referred to more favorably in the media.
Summary
Daré Bioscience beats CASI Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get CASI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CASI Pharmaceuticals Competitors List
Related Companies and Tools
